JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 3 filers reported holding JUNO THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $319,692,000 | +6.1% | 6,993,901 | +4.1% | 0.01% | 0.0% |
Q3 2017 | $301,269,000 | +60.4% | 6,715,753 | +6.8% | 0.01% | +55.6% |
Q2 2017 | $187,879,000 | +37.6% | 6,285,676 | +2.1% | 0.01% | +28.6% |
Q1 2017 | $136,553,000 | +23.8% | 6,153,812 | +5.2% | 0.01% | +16.7% |
Q4 2016 | $110,271,000 | -34.8% | 5,849,900 | +3.8% | 0.01% | -40.0% |
Q3 2016 | $169,075,000 | -19.6% | 5,633,937 | +3.0% | 0.01% | -23.1% |
Q2 2016 | $210,331,000 | +15.9% | 5,471,650 | +14.8% | 0.01% | +8.3% |
Q1 2016 | $181,481,000 | -10.6% | 4,764,510 | +3.2% | 0.01% | -14.3% |
Q4 2015 | $202,937,000 | -43.0% | 4,615,355 | -47.3% | 0.01% | +7.7% |
Q3 2015 | $356,220,000 | +377.9% | 8,754,490 | +526.3% | 0.01% | +160.0% |
Q2 2015 | $74,546,000 | -9.2% | 1,397,829 | +3.3% | 0.01% | -16.7% |
Q1 2015 | $82,081,000 | +2145.7% | 1,353,132 | +1833.0% | 0.01% | – |
Q4 2014 | $3,655,000 | – | 70,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |